Haleon to acquire an additional 33% stake in Tianjin TSKF Pharmaceutical for $636m.

Haleon, a British multinational consumer healthcare company, agreed to acquire an additional 33% stake in Tianjin TSKF Pharmaceutical, a pharmaceutical company, for $636m. "China is a key strategic market for Haleon. Over the last three years, it has delivered strong market share growth and our acquisition of a further 33% in our JV partnership is an important milestone which is both strategically and commercially compelling. It reflects our commitment to this important market, the exceptional growth potential we see in China and is fully consistent with our capital allocation priorities to drive attractive returns for shareholders and maintain a strong investment grade balance sheet," Brian McNamara, Haleon CEO.